Billionaire Investor Stanley Druckenmiller’s Unconventional Bet on Revolution Medicines

Imagine running a fund for 30 years, including during the aftermath of the dot-com bubble bursting and the financial crisis of 2008, without a single losing year. If you’re Stanley Druckenmiller, no imagination is required. He achieved this feat for Duquesne Capital Management between 1981 and 2010, delivering an average annual return of roughly 30%.

Druckenmiller no longer runs Duquesne Capital Management after deciding to close shop in 2010. However, he does manage the Duquesne Family Office, a private investment firm that handles his and his family’s money. The billionaire’s impressive track record has led many investors to pay attention to which stocks he likes, and Druckenmiller continues to load up on Revolution Medicines (NASDAQ: RVMD), a biotech stock for which analysts have only modest near-term growth expectations.

At first glance, it seems counterintuitive for a successful investor like Druckenmiller to bet big on a company with limited near-term growth prospects. However, a closer look at Revolution Medicines’ pipeline reveals a promising future for the biotech innovator. The company awaits U.S. Food and Drug Administration (FDA) approval of daraxonrasib for previously treated metastatic pancreatic cancer, a drug that has shown positive results in a Phase 3 clinical trial.

Analysts’ peak annual sales projections for daraxonrasib range from $5 billion to $7.6 billion, assuming it’s approved to treat pancreatic cancer. Revolution Medicines is also evaluating daraxonrasib in a late-stage study to treat non-small cell lung cancer (NSCLC). The company’s pipeline features other promising candidates, including zoldonrasib, which is being evaluated in late-stage trials for treating both pancreatic cancer and NSCLC.

Druckenmiller’s enthusiasm for Revolution Medicines is evident in his increasing stake in the company. In the second quarter of 2026, he initiated a position in the biotech innovator and increased his family office’s stake by 26.5%. While Wall Street analysts have only modest near-term growth expectations for Revolution Medicines, Druckenmiller’s bet on the company’s pipeline suggests that he believes in its long-term potential.

Revolution Medicines’ market cap is around $45 billion, and it has no approved products yet. Buying stock in the company is certainly not for the faint of heart. However, Druckenmiller’s strategy of swinging for the fence could pay off handsomely if daraxonrasib wins approval. The question remains: does Druckenmiller know something that Wall Street doesn’t?

The answer lies in his long-term perspective. Druckenmiller is focused on the future rather than the present and the past. His investment strategy is centered on identifying companies with promising pipelines and waiting for the market to catch up. While it’s impossible to predict the future, Druckenmiller’s track record suggests that he has a keen eye for spotting undervalued companies with strong growth potential.

As the market continues to evolve, it’s essential to keep an eye on Druckenmiller’s investments. Will his bet on Revolution Medicines pay off, or will it be another example of his bold but ultimately unsuccessful investment strategy? Only time will tell.